The Concentration of CMKLR1 Expression on Clinicopathological Parameters of Colorectal Cancer: A Preliminary Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Sample
2.2. Preparation of Samples for the Evaluation of CMKLR1 Level (T- Tumor Size, N- Lymphatic Nodes Involvement, M- Distant Metastases, G- Grading)
2.3. Evaluation of CMKLR1 Level
2.4. Immunostaining
2.5. Histological Evaluation
2.6. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- International Agency for Research on Cancer (Switzerland) Global Cancer Observatory. Available online: https://gco.iarc.fr/ (accessed on 21 February 2021).
- Nagtegaal, I.D.; Odze, R.D.; Klimstra, D.; Paradis, V.; Rugge, M.; Schirmacher, P.; Washington, K.M.; Carneiro, F.; Cree, I.A. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020, 76, 182–188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ahmadi, O.; Stringer, M.D.; Black, M.A.; McCall, J.L. Clinico-pathological factors influencing lymph node yield in colorectal cancer and impact on survival: Analysis of New Zealand Cancer Registry data. J. Surg. Oncol. 2015, 111, 451–458. [Google Scholar] [CrossRef] [PubMed]
- Perrott, S.; Laurie, K.; Laws, K.; Johnes, A.; Miedzybrodzka, Z.; Samuel, L. Young-onset colorectal cancer in the North East of Scotland: Survival, clinico-pathological features and genetics. BMC Cancer 2020, 20, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakamura, N.; Naruse, K.; Kobayashi, Y.; Miyabe, M.; Saiki, T.; Enomoto, A.; Takahashi, M.; Matsubara, T. Chemerin promotes angiogenesis in vivo. Physiol. Rep. 2018, 6, e13962. [Google Scholar] [CrossRef]
- Meder, W.; Wendland, M.; Busmann, A.; Kutzleb, C.; Spodsberg, N.; John, H.; Richter, R.; Schleuder, D.; Meyer, M.; Forssmann, W.G. Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23. FEBS Lett. 2003, 555, 495–499. [Google Scholar] [CrossRef] [Green Version]
- Bondue, B.; Wittamer, V.; Parmentier, M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 2011, 22, 331–338. [Google Scholar] [CrossRef] [Green Version]
- Roh, S.; Song, S.-H.; Choi, K.-C.; Katoh, K.; Wittamer, V.; Parmentier, M.; Sasaki, S. Chemerin-A new adipokine that modulates adipogenesis via its own receptor. Biochem. Biophys. Res. Commun. 2007, 362, 1013–1018. [Google Scholar] [CrossRef] [Green Version]
- Kaur, J.; Adya, R.; Tan, B.K.; Chen, J.; Randeva, H.S. Identification of chemerin receptor (ChemR23) in human endothelial cells: Chemerin-induced endothelial angiogenesis. Biochem. Biophys. Res. Commun. 2010, 391, 1762–1768. [Google Scholar] [CrossRef] [Green Version]
- Kumar, J.D.; Kandola, S.; Tiszlavicz, L.; Reisz, Z.; Dockray, G.J.; Varro, A. The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells. Br. J. Cancer 2016, 114, 1152–1159. [Google Scholar] [CrossRef] [Green Version]
- Iseki, Y.; Shibutani, M.; Maeda, K.; Nagahara, H.; Fukuoka, T.; Matsutani, S.; Kashiwagi, S.; Tanaka, H.; Hirakawa, K.; Ohira, M. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS ONE 2018, 13, e0192744. [Google Scholar] [CrossRef]
- Yin, L.; Li, J.; Ma, D.; Li, D.; Sun, Y. Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies. Oncol. Lett. 2020, 19, 3558–3566. [Google Scholar] [CrossRef]
- De Smedt, L.; Palmans, S.; Sagaert, X. Tumour budding in colorectal cancer: What do we know and what can we do? Virchows Arch. 2016, 468, 397–408. [Google Scholar] [CrossRef] [PubMed]
- Chabowski, M.; Nowak, A.; Grzegrzolka, J.; Piotrowska, A.; Janczak, D.; Dziegiel, P. Comparison of Microvessel Density Using Nestin and CD34 in Colorectal Cancer. Anticancer Res. 2018, 38, 3889–3895. [Google Scholar] [CrossRef]
- Salgado, R.; Denkert, C.; Demaria, S.; Sirtaine, N.; Klauschen, F.; Pruneri, G.; Wienert, S.; van den Eynden, G.; Baehner, F.L.; Penault-Llorca, F.; et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015, 26, 259–271. [Google Scholar] [CrossRef] [PubMed]
- Kiczmer, P.; Seńkowska, A.P.; Kula, A.; Dawidowicz, M.; Strzelczyk, J.K.; Zajdel, E.N.; Walkiewicz, K.; Waniczek, D.; Ostrowska, Z.; Świętochowska, E. Assessment of CMKLR1 level in colorectal cancer and its correlation with angiogenic markers. Exp. Mol. Pathol. 2020, 113, 104377. [Google Scholar] [CrossRef]
- Kumar, J.D.; Aolymat, I.; Tiszlavicz, L.; Reisz, Z.; Garalla, H.M.; Beynon, R.; Simpson, D.; Dockray, G.J.; Varro, A. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: Putative role of decreased TIMP-1 and TIMP-2. Oncotarget 2019, 10, 98–112. [Google Scholar] [CrossRef] [Green Version]
- Wang, C.; Wu, W.K.K.; Liu, X.; To, K.-F.; Chen, G.G.; Yu, J.; Ng, E.K.W. Increased serum chemerin level promotes cellular invasiveness in gastric cancer: A clinical and experimental study. Peptides 2014, 51, 131–138. [Google Scholar] [CrossRef]
- Huang, X.; Fu, C.; Liu, W.; Liang, Y.; Li, P.; Liu, Z.; Sheng, Q.; Liu, P. Chemerin-induced angiogenesis and adipogenesis in 3 T3-L1 preadipocytes is mediated by lncRNA Meg3 through regulating Dickkopf-3 by sponging miR-217. Toxicol. Appl. Pharmacol. 2019, 385, 114815. [Google Scholar] [CrossRef]
- Mielcarska, S.; Stopińska, K.; Dawidowicz, M.; Kula, A.; Kiczmer, P.; Seńkowska, A.P.; Zajdel, E.N.; Walkiewicz, K.; Waniczek, D.; Świętochowska, E. GDF-15 Level Correlates with CMKLR1 and VEGF-A in Tumor-free Margin in Colorectal Cancer. Curr. Med. Sci. 2021, 41, 522–528. [Google Scholar] [CrossRef]
- Sammarco, G.; Gallo, G.; Vescio, G.; Picciariello, A.; de Paola, G.; Trompetto, M.; Currò, G.; Ammendola, M. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. J. Clin. Med. 2020, 9, 2852. [Google Scholar] [CrossRef] [PubMed]
- Den Uil, S.H.; van den Broek, E.; Coupé, V.M.H.; Vellinga, T.T.; Delis-van Diemen, P.M.; Bril, H.; Belt, E.J.T.; Kranenburg, O.; Stockmann, H.B.A.C.; Belien, J.A.M.; et al. Prognostic value of microvessel density in stage II and III colon cancer patients: A retrospective cohort study. BMC Gastroenterol. 2019, 19, 146. [Google Scholar] [CrossRef]
- Dewhirst, M.W.; Secomb, T.W. Transport of drugs from blood vessels to tumour tissue. Nat. Rev. Cancer 2017, 17, 738–750. [Google Scholar] [CrossRef]
- Wang, N.; Wang, Q.-J.; Feng, Y.-Y.; Shang, W.; Cai, M. Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin. Oral Investig. 2014, 18, 997–1004. [Google Scholar] [CrossRef]
- Lin, Y.; Yang, X.; Liu, W.; Li, B.; Yin, W.; Shi, Y.; He, R. Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation. Oncogene 2017, 36, 3599–3608. [Google Scholar] [CrossRef] [PubMed]
- Chua, S.-K.; Shyu, K.-G.; Lin, Y.-F.; Lo, H.-M.; Wang, B.-W.; Chang, H.; Lien, L.-M. Tumor Necrosis Factor-Alpha and the ERK Pathway Drive Chemerin Expression in Response to Hypoxia in Cultured Human Coronary Artery Endothelial Cells. PLoS ONE 2016, 11, e0165613. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morodomi, T.; Isomoto, H.; Shirouzu, K.; Kakegawa, K.; Irie, K.; Morimatsu, M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989, 63, 539–543. [Google Scholar] [CrossRef]
- Brabletz, T.; Jung, A.; Reu, S.; Porzner, M.; Hlubek, F.; Kunz-Schughart, L.A.; Knuechel, R.; Kirchner, T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 2001, 98, 10356–10361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Talbot, L.J.; Bhattacharya, S.D.; Kuo, P.C. Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int. J. Biochem. Mol. Biol. 2012, 3, 117–136. [Google Scholar]
- Zlobec, I.; Lugli, A.; Baker, K.; Roth, S.; Minoo, P.; Hayashi, S.; Terracciano, L.; Jass, J.R. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J. Pathol. 2007, 212, 260–268. [Google Scholar] [CrossRef]
- Zlobec, I.; Hädrich, M.; Dawson, H.; Koelzer, V.H.; Borner, M.; Mallaev, M.; Schnüriger, B.; Inderbitzin, D.; Lugli, A. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br. J. Cancer 2014, 110, 1008–1013. [Google Scholar] [CrossRef]
- García-Solano, J.; Conesa-Zamora, P.; Trujillo-Santos, J.; Torres-Moreno, D.; Mäkinen, M.J.; Pérez-Guillermo, M. Immunohistochemical expression profile of β-catenin, E-cadherin, P-cadherin, laminin-5γ2 chain, and SMAD4 in colorectal serrated adenocarcinoma. Hum. Pathol. 2012, 43, 1094–1102. [Google Scholar] [CrossRef]
- Zlobec, I.; Lugli, A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget 2010, 1, 651–661. [Google Scholar] [CrossRef] [Green Version]
- Cao, H.; Xu, E.; Liu, H.; Wan, L.; Lai, M. Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review. Pathol. Res. Pract. 2015, 211, 557–569. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.; Lee, J.-H.; Lee, S.K.; Song, N.-Y.; Son, S.H.; Kim, K.R.; Chung, W.-Y. Chemerin Treatment Inhibits the Growth and Bone Invasion of Breast Cancer Cells. Int. J. Mol. Sci. 2020, 21, 2871. [Google Scholar] [CrossRef] [Green Version]
- Zlobec, I.; Minoo, P.; Terracciano, L.; Baker, K.; Lugli, A. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology 2011, 59, 482–495. [Google Scholar] [CrossRef] [PubMed]
- Brown, M.; Sillah, K.; Griffiths, E.A.; Swindell, R.; West, C.M.; Page, R.D.; Welch, I.M.; Pritchard, S.A. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology 2010, 56, 893–899. [Google Scholar] [CrossRef]
- Pachynski, R.K.; Zabel, B.A.; Kohrt, H.E.; Tejeda, N.M.; Monnier, J.; Swanson, C.D.; Holzer, A.K.; Gentles, A.J.; Sperinde, G.V.; Edalati, A.; et al. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J. Exp. Med. 2012, 209, 1427–1435. [Google Scholar] [CrossRef] [PubMed]
- Treeck, O.; Buechler, C.; Ortmann, O. Chemerin and Cancer. Int. J. Mol. Sci. 2019, 20, 3750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rennier, K.; Shin, W.J.; Krug, E.; Virdi, G.; Pachynski, R.K. Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade. Clin. Cancer Res. 2020, 26, 5019–5035. [Google Scholar] [CrossRef] [PubMed]
n | % | ||
---|---|---|---|
T | 1 | 0 | 0.00 |
2 | 14 | 32.56 | |
3 | 20 | 46.51 | |
4 | 9 | 20.93 | |
N | 0 | 26 | 60.47 |
1 | 11 | 25.58 | |
2 | 6 | 13.95 | |
M | 0 | 35 | 81.40 |
1 | 8 | 18.60 | |
G | 1 | 3 | 6.98 |
2 | 38 | 88.37 | |
3 | 2 | 4.65 | |
Stage | I | 12 | 27.91 |
II | 11 | 25.58 | |
III | 12 | 27.91 | |
IV | 8 | 18.60 |
CMKLR1 Concentration | Mean | SD | p |
---|---|---|---|
Log CMKLR1 tumor | −1.09 | 0.40 | <0.0001 |
Log CMKLR1 margin | −1.38 | 0.41 |
Histological Parameter | |||||
---|---|---|---|---|---|
n | Mean | Min | Max | SD | |
MVD | 35 | 64.82 | 35.46 | 97.10 | 17.58 |
n | % | ||
---|---|---|---|
Budding | 0–4 | 29 | 67.44 |
5–9 | 5 | 11.63 | |
>10 | 9 | 20.93 | |
TILs | 0–5% | 14 | 32.56 |
6–25% | 17 | 39.53 | |
26–50% | 8 | 18.60 | |
51–75% | 3 | 6.98 | |
>75% | 1 | 2.33 |
CMKLR1 Concentration | n = 43 | ||
---|---|---|---|
Tau | p | ||
Log CMKLR1 tumor | TILS | 0.18 | 0.09 |
Budding | −0.21 | 0.05 | |
Log CMKLR1 margin | TILS | −0.07 | 0.51 |
Budding | −0.22 | 0.03 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kiczmer, P.; Mielcarska, S.; Chrabańska, M.; Dawidowicz, M.; Kula, A.; Rynkiewicz, M.; Seńkowska, A.P.; Waniczek, D.; Piecuch, J.; Jopek, J.; et al. The Concentration of CMKLR1 Expression on Clinicopathological Parameters of Colorectal Cancer: A Preliminary Study. Medicina 2021, 57, 1299. https://doi.org/10.3390/medicina57121299
Kiczmer P, Mielcarska S, Chrabańska M, Dawidowicz M, Kula A, Rynkiewicz M, Seńkowska AP, Waniczek D, Piecuch J, Jopek J, et al. The Concentration of CMKLR1 Expression on Clinicopathological Parameters of Colorectal Cancer: A Preliminary Study. Medicina. 2021; 57(12):1299. https://doi.org/10.3390/medicina57121299
Chicago/Turabian StyleKiczmer, Paweł, Sylwia Mielcarska, Magdalena Chrabańska, Miriam Dawidowicz, Agnieszka Kula, Magdalena Rynkiewicz, Alicja Prawdzic Seńkowska, Dariusz Waniczek, Jerzy Piecuch, Janusz Jopek, and et al. 2021. "The Concentration of CMKLR1 Expression on Clinicopathological Parameters of Colorectal Cancer: A Preliminary Study" Medicina 57, no. 12: 1299. https://doi.org/10.3390/medicina57121299